Los Angeles Health Care Fraud Takedown Charges 15 Defendants in Schemes Involving More Than $1.8 Billion in Claims

On October 22, 2026, the Department of Justice (DOJ) announced criminal charges against 15 defendants, including six medical professionals, in alleged healthcare fraud schemes involving more than $1.8 billion in claims submitted to government and private healthcare programs. The coordinated Los Angeles takedown spans substance abuse treatment, invasive vascular procedures, hospice care, genetic testing, pharmacy billing, and the sale of prescription drug samples.

The largest alleged scheme concerns more than $1.6 billion billed for substance abuse treatment. Prosecutors allege that four defendants targeted vulnerable individuals, including people experiencing homelessness and poverty, and induced them to travel to California and other locations with offers of housing, transportation, cash, drugs, and other benefits. The defendants allegedly recycled patients through facilities, coached them to fabricate symptoms, and billed insurers for treatment that was medically unnecessary, nonexistent, or materially different from the services represented.

A separate indictment alleges that a cardiothoracic surgeon and a chiropractor billed Medicare approximately $135 million for medically unnecessary atherectomies. According to the government, some patients did not have the arterial disease being treated, repeat procedures were performed after unsuccessful earlier interventions, and claims were submitted under the names of providers who did not perform the procedures. The government stated that claims data identified the surgeon as an extreme national outlier for atherectomy billing.

The takedown also includes three hospice matters involving more than $138 million in alleged false claims. The charging documents describe the enrollment of beneficiaries who were not terminally ill, false or incomplete certifications of terminal illness, fabricated clinical records, patient cycling among related hospices, and referral payments to marketers and beneficiaries. The government also cited unusually high non-death discharge rates as an indicator that patients did not satisfy hospice eligibility requirements.

Other cases allege kickbacks for unnecessary genetic tests, a nearly $270 million Medi-Cal pharmacy scheme involving bogus prescriptions for high-reimbursing drugs, and the unlawful sale of prescription drug samples.

Data Analytics and Patient Harm

The announcement is notable for pairing claims-data anomalies with patient harm and compromised clinical judgment. The government tied outlier utilization to alleged unnecessary procedures, false diagnoses and certifications, billing under another provider’s name, and patient inducements. Providers should use internal analytics to identify unusual procedure volumes, discharge patterns, referral concentrations, and abrupt shifts in product or service mix before those patterns attract scrutiny.

The charges under the Eliminating Kickbacks in Recovery Act (EKRA) are especially notable because criminal enforcement under EKRA remains comparatively uncommon. EKRA prohibits remuneration for referrals to recovery homes, clinical treatment facilities, or laboratories when services are covered by a health care benefit program. Unlike the federal Anti-Kickback Statute (AKS), EKRA can reach commercial insurance. Providers and laboratories should evaluate marketer, employee, and contractor compensation under EKRA’s text and exceptions rather than assume non-federal program arrangements are beyond federal kickback exposure.

The cases also underscore the need to test whether documentation and ordering controls reflect independent clinical judgment. Substance abuse and hospice providers should scrutinize marketer compensation, patient benefits, eligibility certifications, discharge data, and affiliated ownership. Physician practices, laboratories, and pharmacies should verify medical necessity, valid orders, accurate rendering-provider information, and authentic prescriptions, and investigate sudden high-volume use of high-reimbursing products.

GWB represents healthcare providers and other organizations in connection with government investigations and enforcement actions. If you need assistance with such a matter, contact us today.